Premium
Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F‐ FDG PET
Author(s) -
Cribe AnneSofie Weindel Ibar,
Steenhof Maria,
Marcher Claus Werenberg,
Petersen Henrik,
Frederiksen Henrik,
Friis Lone Smidstrup
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12085
Subject(s) - medicine , myeloid leukemia , positron emission tomography , induction chemotherapy , bone marrow , chemotherapy , radiology , physical examination , leukemia , myeloid , nuclear medicine
Background Prevalence of extramedullary disease ( EMD ) in acute myeloid leukemia ( AML ) at the time of diagnosis is unknown. Previous estimates range from 2.5% to 30.5% and are usually based on clinical examination. This may cause an under diagnosis of EMD as not all extramedullary manifestations are easily detectable. Few recent studies have used positron emission tomography ( PET ) scans for diagnosing EMD in patients AML . Method During a 9‐month period, newly diagnosed patients with AML who were candidates for intensive chemotherapy were 18F‐Fluoro‐deoxy‐glucose ( FDG ) PET ‐scanned prior to induction treatment. We compared the prevalence of EMD diagnosed by PET scans and by clinical examination. Subsequent PET scans following induction chemotherapy were performed for response evaluation of EMD . Results Twenty‐six patients were included in the study. 18‐F‐ FDG PET scans revealed more than twice as many patients with EMD than found by clinical examination (65% vs. 31%). PET demonstrated 55 EMD lesions compared with 15 diagnosed by clinical examination. In general, the responses of EMD detected by PET scans were concordant with the bone marrow responses assessed by pathology examination. Conclusion 18‐F‐ FDG PET is a useful tool for diagnosing EMD in AML and for assessing treatment responses of EMD in AML .